Physician profile
Sandra Lee
NPI 1871955575
$1,435.27
in general payments reported to CMS, 2019-2025
19 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.82 · 2020: $120 · 2021: $730 · 2022: $37.01 · 2023: $22.93 · 2024: $142 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $319.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $269.07 | 2021-2025 | |
| Lilly USA, LLC | $237.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $94.77 | 2020-2025 | Arexvy, Shingrix |
| Pfizer INC. | $92.58 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $74.29 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $51.74 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.23 | 2021-2022 | |
| Exact Sciences Corporation | $40.22 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $34.53 | 2021 | |
| Insulet Corporation | $32.98 | 2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $25.51 | 2020-2021 | |
| Ucb, INC. | $21.95 | 2019 | |
| Biogen, INC. | $19.42 | 2021 | |
| Merck Sharp & Dohme LLC | $17.97 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $16.75 | 2020 | |
| Currax Pharmaceuticals LLC | $16.27 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.98 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.